Delivery Order SPE2DB24D1104-SPE2DB25FYEM2
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) under a firm fixed-price contract valued at $1,664.74. The award, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a non-competitive delivery order without set-aside designation. Performance will be executed from the contractor's facility in Conshohocken, Pennsylvania, the company's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $8,939.49 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets (30-count packages) on July 29, 2025, with completion scheduled for July 30, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of the company's role as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Ondansetron ODT 4 mg tablets in a 30-count quantity, with a ceiling value of $4,245.12. This firm fixed price delivery order represents a competitively awarded contract with no set-aside designation and is scheduled for ultimate completion by July 28, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,774.90 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) under a firm fixed-price contract. The award was made on August 4, 2025, with an ultimate completion date of August 5, 2025, and is to be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a non-set-aside, competitively awarded transaction for pharmaceutical supplies to support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,882.56 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This is a firm fixed price delivery order with no set-aside designation, competitively awarded and completed on August 8, 2025. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,792.97 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count packaging) on July 22, 2025, with an ultimate completion date of July 23, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and designates Conshohocken, Pennsylvania as the place of performance. The delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $4,958.04 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This competitively awarded, firm fixed-price delivery order was issued on July 23, 2025, with an ultimate completion date of July 24, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this procurement. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $5,996.73 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order was executed on August 14, 2025, with an ultimate completion date of August 15, 2025. The contract does not include a set-aside designation. Performance will be fulfilled from AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,478.44 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count package). This competitively awarded, firm fixed price delivery order was issued on July 29, 2025, with an ultimate completion date of July 30, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office. No set-aside designation was applied...
- The Defense Logistics Agency awarded a delivery order valued at $5,660.39 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets (30-count packages) with a firm fixed price structure. The contract, awarded July 31, 2025, represents a non-set-aside, competitively awarded delivery order with an ultimate completion date of August 1, 2025. Performance will be executed from the vendor's location in Conshohocken, Pennsylvania, the company's corporate headquarters. This...
- SPE2DB24D1104Indefinite Delivery Contract
- SPE2DB24D1104-SPE2DB25FYEM2Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,683.30 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) on August 12, 2025, with completion scheduled for August 13, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a pharmaceutical supply requirement within DLA's broader medical procurement operations supporting U.S. military and federal healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's prime indefinite delivery contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical vendor agreement valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp serves as a critical supplier of medications, vaccines, and medical supplies across multiple therapeutic areas to support Defense Health Agency operations and other federal healthcare customers. The company's extensive portfolio and proven capability to fulfill federal procurement requirements through open competition positions it as a primary vendor within DLA's global pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.7k | 8/12/25 |